Back

Long-term continuation to pharmacological treatment for secondary prevention after a myocardial infarction: a register study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Secondary prevention: a multifactorial approach Secondary Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Maria Sakalaki

Sahlgrenska Academy, Gothenburg (Sweden)

9 More presentations in this session

Presentation thumbnail
Comprehensive risk factor management through a dedicated secondary prevention clinic: experience from hamilton, Ontario
Miss C. Frketich (Hamilton, CA)
Abstract Slides Video
Presentation thumbnail
Variability of pre-test probability for obstructive coronary artery disease between referring primary care physicians and estimations from the referral letters
Mr E. Stertman (Linkoping, SE)
Abstract Slides Video
Presentation thumbnail
Integrated care using the ABC-stroke pathway improves cardiovascular outcomes and survival in patients with recent ischaemic stroke: a population-based cohort study
Doctor S. Choi (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
National dispensing of evidence-based treatment for New Zealand patients before and after peripheral arterial or percutaneous coronary procedures; undertreatment in plain sight.
Associate Professor S. Wells (Auckland, NZ)
Abstract Slides Video
Presentation thumbnail
Prolonged dual antiplatelet therapy in an extended Phase 3 Cardiac Rehabilitation Program following myocardial infarction
Doctor H. Merenciano Gonzalez (Valencia, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention: a multifactorial approach

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
High rates of discontinuation and reinitiation of secondary preventive medications after a first myocardial infarction
thumbnail
Congress Presentation
Beta-blocker duration and long-term cardiovascular risk after myocardial infarction with reduced ejection fraction
thumbnail
Congress Presentation
The effect of discontinuing long-term beta-blockers following acute myocardial infarction in optimally treated, stable patients without heart failure - a Danish, nationwide cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources